×
Click here if your patients are having issues using their co-pay card or their co-pay is higher than normal at the pharmacy.

Indication Aimovig® is indicated for the preventive treatment of migraine in adults.

Committed to helping your patients access Aimovig®

Aimovig Has Broad Coverage
94% of patients are covered for Aimovig® treatment

*87% of patients are covered for Aimovig® based on MMIT data of commercial, Medicare, and Medicaid covered lives. Based on reported coverage as of February 2024.3 Product coverage is determined by the payer and is subject to change without notice.

Kathi_MobilePooja, real Aimovig® patient since 2018.
Aimovig® patient, Pooja, at a restaurantPooja, real Aimovig® patient since 2018.

Aimovig® is the first-approved anti-CGRP pathway treatment for migraine prevention

Since 2018, Aimovig® offered patients like Pooja more days without migraine1,2

In a phase 3, randomized, controlled study, Aimovig® reduced the number of monthly migraine days during Months 4-6.1

Individual results may vary.

Long-term efficacy data with results out to 5 years

EXPLORE THE EFFICACY DATA

Aimovig® has broad coverage

EXPLORE COVERAGE AND ACCESS

Aimovig Copay Card® can lower out-of-pocket costs for eligible commercial patients

EXPLORE AFFORDABILITY

Sustained migraine prevention is possible, and fewer monthly migraine days could mean a life dictated less by migraine1

INDICATION

Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.

Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe 

References: 1. Aimovig® (erenumab-aooe) Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2021. 2. Data on file, Amgen; 2023.